Taro Pharmaceutical Industries (NYSE:TARO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a report released on Sunday. The brokerage issued a strong-buy rating on the stock.

Separately, HC Wainwright downgraded Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 price target on the stock. in a report on Thursday, January 18th.

Taro Pharmaceutical Industries Stock Down 0.3 %

NYSE TARO opened at $42.30 on Friday. Taro Pharmaceutical Industries has a 52 week low of $27.87 and a 52 week high of $45.76. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of 34.67 and a beta of 0.60. The company has a fifty day moving average of $42.18 and a two-hundred day moving average of $40.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brandes Investment Partners LP raised its position in shares of Taro Pharmaceutical Industries by 0.7% in the 4th quarter. Brandes Investment Partners LP now owns 475,741 shares of the company’s stock worth $19,876,000 after acquiring an additional 3,253 shares in the last quarter. Invesco Ltd. purchased a new position in shares of Taro Pharmaceutical Industries in the 3rd quarter worth approximately $9,995,000. UBS Group AG raised its stake in shares of Taro Pharmaceutical Industries by 56.6% during the 3rd quarter. UBS Group AG now owns 54,175 shares of the company’s stock worth $2,043,000 after acquiring an additional 19,588 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Taro Pharmaceutical Industries by 1.4% during the third quarter. Bank of New York Mellon Corp now owns 22,223 shares of the company’s stock valued at $838,000 after acquiring an additional 307 shares during the last quarter. Finally, Inspire Advisors LLC boosted its stake in Taro Pharmaceutical Industries by 5.9% in the first quarter. Inspire Advisors LLC now owns 14,495 shares of the company’s stock valued at $614,000 after acquiring an additional 813 shares in the last quarter. 91.40% of the stock is currently owned by institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.